Lavezoli will lead Curia’s biologics division, overseeing its discovery, development and manufacturing services.
“This is an exciting time for our biologics team and we are pleased to have Steve on board,” said Curia CEO Philip Macnabb.
“Steve’s remarkable breadth of experience leading commercial operations for biologics development and manufacturing makes him a natural fit to lead our biologics efforts. Under his guidance, I have every confidence that we will further our mission of life-changing life science.”
Lavezoli most recently worked for Scorpius Biologics, a startup CDMO focused on microbial and mammalian biologics development and manufacturing as the Vice President of Commercial Operations.
Prior to joining Scorpius, he spent four years with Catalent Biologics, focused on drug substance business development in the US for early stage clinical programmes and later focusing on late-stage commercial programme integration.
He also spent 12 years in the industrial gasses industry with Linde Gas before joining W.L. Gore in the startup biopharmaceutical division to work on a commercial business/market development role for bulk drug substance single-use items.
He earned his BS in chemical engineering from Pennsylvania State University.
“Curia holds a unique position in the CDMO industry with an impressive end-to-end offering,” said Lavezoli. “It’s an honour to join a team with such deep scientific expertise and values-driven purpose to drive a positive impact on patients’ lives.”
